GiT Updates and More

Surveillance of Barrett’s oesophagus according to 2025 guidelines

Do PPIs still work for EoE?

Advances in the pathophysiology, diagnosis, and management of celiac disease.

BMJ 2025

PDF 👇

Eosinophilic esophagitis: step up 🆚 step down #ACG2025

Dieulafoy in the proximal stomach. hot biopsy forceps is preferred here. Cheap, retroflexes, securely grips the vessel and gives feedback you got the vessel. Plus the stomach can’t take the heat (60W soft coagulation)!

Choosing Advanced Therapies for UC Based on Concomitant Immune Conditions and Extra-Intestinal Manifestations. #ACG2025

❇️ Navigating Therapies in Inflammatory Bowel Disease: Strategic Positioning of Emerging Drugs #ACG2025 PDF 👇

Gastroparesis and functional dyspepsia are challenging in part due to multiple possible pathophysiological contributors #ACG2025

Proton Pump Inhibitors for Inducing and Maintaining Remission in Eosinophilic Esophagitis: An Updated Systematic Review and Meta-Analysis PDF 👇

Clinical Gastroenterology and Hepatology October 2025

❇️ The statistical Summary: ➡️ Previous TNF exposure ↓ efficacy of lymphocyte trafficking inhibitors. ➡️ Previous TNF exposure ↑ or maintains efficacy of JAK inhibitors. ➡️ No major change with IL-23 blockers.

Clinical Gastroenterology and Hepatology October 2025

PDF 👇

❇️ Identification of Patients With Non cirrhotic Clinically Significant Fibrosis (F2-F3) ➡️ How to Rule-in F4: Presence of Any One of the Following Suggests a Substantial Risk of Cirrhosis

Definitions of Ambulatory-Aki in Cirrhotic patients

Cholecystectomy is a Risk Factor for Microscopic Colitis: ANationwide Population-Based Case-Control Study

Clinical Gastroenterology and Hepatology October 2025

PDF 👇

Real-World Effectiveness and Safety of Upadacitinib in Crohn’s disease: AMulti-Centre Study

Clinical Gastroenterology and Hepatology October 2025

A Phase 3 Biomarker Validation of GALAD for the Detection of Hepatocellular Carcinoma in Cirrhosis. PDF